Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
About this trial
This is an interventional treatment trial for Idiopathic Pulmonary Fibrosis
Eligibility Criteria
Inclusion Criteria: Patients will be eligible for enrolment if diagnosed with Mild exacerbation of IPF and admitted to the Chest Department of Assiut University, requiring ventilator support without invasive mechanical ventilation. Exclusion Criteria: Age: less than 18 years. Patients with any severity other than mild Acute exacerbation of IPF Patients with MSCT with a radiological pattern rather than UIP Unstable patients need mechanical ventilation or RICU admission Patients with end-organ failure.
Sites / Locations
- Assiut university-Faculty of Medicine
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Conventional therapy group
Add-on Azithromycin
Patients will receive conventional treatment for acute exacerbation of IPF, including pulse corticosteroid therapy and supportive treatment, and oxygen therapy.
Patients will receive conventional therapy and Add-on Azithromycin 500 mg single daily dose for five days